Pier Lindenbergh
PhD candidate
- Name
- P.P. Lindenbergh
- Telephone
- +31 71 527 2727
- p.p.lindenbergh@lacdr.leidenuniv.nl
- ORCID iD
- 0009-0003-4816-2455
PhD candidate
- Science
- Leiden Academic Centre for Drug Research
- LACDR/Biopharmaceutics
- Delfos L, Depuydt M.A.C., Chemaly M., Coyle S., Schaftenaar F.H., Santbrink P.J. van, Lindenbergh P.P., Bernabé Kleijn M.N.A., Costello C., Power C.A., Coll R., Peace A., Gregory-Ksander M., Foks A.C., Kuiper J., McGilligan V., BotI. & (2025), NLRP3 Inflammasome Inhibition by the Novel Bispecific Antibody InflamAb Attenuates Atherosclerosis in Apolipoprotein E–Deficient Mice, Elsevier : .
- Zhao G., Forn Cuní G., Scheers M., Lindenberg P.P., Yin J., Loosen Q. van, Passarini L., Chen L. & Snaar-Jagalska B.E. (2024), Simultaneous targeting of AMPK and mTOR is a novel therapeutic strategy against prostate cancer, Cancer Letters 587: 216657.